Clinical and histopathologic characteristics and treatments of patients with DLBCL
| Clinical features at diagnosis . | Patients . |
|---|---|
| Male sex, no. patients/all patients (%) | 57/114 (50) |
| Median age, y (range) | 67 (21-86) |
| Adjusted-age IPI, no. patients/all patients (%) | |
| 0-1 y | 35/114 (31) |
| 2-3 y | 79/114 (69) |
| LDH > normal value | 56/114 (49) |
| WHO DLBCL classification, no. patients/all patients (%) | |
| Unspecified | 109/114 (96) |
| T-cell/histiocyte-rich large B-cell lymphoma | 4/114 (3) |
| Intravascular large B-cell lymphoma | 1/114 (1) |
| GCB-ABC subtype | 27/91(30)-64/91(70) |
| First-line treatment, no. patients/all patients (%) | |
| CHOP and CHOP-like regimens | 36/114 (32) |
| R-CHOP and R-CHOP–like regimens | 78/114 (68) |
| Clinical features at diagnosis . | Patients . |
|---|---|
| Male sex, no. patients/all patients (%) | 57/114 (50) |
| Median age, y (range) | 67 (21-86) |
| Adjusted-age IPI, no. patients/all patients (%) | |
| 0-1 y | 35/114 (31) |
| 2-3 y | 79/114 (69) |
| LDH > normal value | 56/114 (49) |
| WHO DLBCL classification, no. patients/all patients (%) | |
| Unspecified | 109/114 (96) |
| T-cell/histiocyte-rich large B-cell lymphoma | 4/114 (3) |
| Intravascular large B-cell lymphoma | 1/114 (1) |
| GCB-ABC subtype | 27/91(30)-64/91(70) |
| First-line treatment, no. patients/all patients (%) | |
| CHOP and CHOP-like regimens | 36/114 (32) |
| R-CHOP and R-CHOP–like regimens | 78/114 (68) |
DLBCL indicates diffuse large B-cell lymphoma; IPI, International Prognostic Index; WHO, World Health Organization; LDH, _; GCB, germinal center B cell; ABC, activated B cell; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; and R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.